Zafgen Inc (NASDAQ:ZFGN) – Analysts at Leerink Swann reduced their Q2 2018 earnings per share (EPS) estimates for Zafgen in a research report issued to clients and investors on Wednesday. Leerink Swann analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings of ($0.54) per share for the quarter, down from their previous forecast of ($0.53). Leerink Swann also issued estimates for Zafgen’s Q3 2018 earnings at ($0.58) EPS, Q4 2018 earnings at ($0.54) EPS, FY2018 earnings at ($2.20) EPS and FY2019 earnings at ($1.64) EPS.
Zafgen (NASDAQ:ZFGN) last issued its quarterly earnings data on Tuesday, March 6th. The biopharmaceutical company reported ($0.48) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.09.
Zafgen (ZFGN) opened at $8.00 on Friday. The stock has a market cap of $219.92, a price-to-earnings ratio of -4.19 and a beta of -0.65. Zafgen has a 52 week low of $3.21 and a 52 week high of $10.00.
Hedge funds have recently added to or reduced their stakes in the company. Mangrove Partners bought a new position in shares of Zafgen during the third quarter valued at $1,971,000. 683 Capital Management LLC raised its stake in shares of Zafgen by 8.5% during the third quarter. 683 Capital Management LLC now owns 1,300,000 shares of the biopharmaceutical company’s stock valued at $4,576,000 after acquiring an additional 101,600 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Zafgen by 1,701.5% during the second quarter. Goldman Sachs Group Inc. now owns 197,287 shares of the biopharmaceutical company’s stock valued at $692,000 after acquiring an additional 186,336 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Zafgen by 31.8% during the second quarter. Dimensional Fund Advisors LP now owns 584,159 shares of the biopharmaceutical company’s stock valued at $2,050,000 after acquiring an additional 140,848 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Zafgen by 15.7% during the second quarter. Vanguard Group Inc. now owns 883,838 shares of the biopharmaceutical company’s stock valued at $3,102,000 after acquiring an additional 119,902 shares during the last quarter. 52.52% of the stock is owned by hedge funds and other institutional investors.
In other news, insider Thomas E. Hughes sold 5,000 shares of the firm’s stock in a transaction on Wednesday, March 7th. The shares were sold at an average price of $10.00, for a total transaction of $50,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 21.20% of the stock is currently owned by company insiders.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.